AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Onxeo Investor Presentation 2015

Jul 8, 2015

1573_iss_2015-07-08_e2e17e94-1d6e-46b8-91e6-685556ae4935.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Meetings with the financial community during the 2nd semester of 2015

Paris (France), Copenhagen (Denmark), July 8, 2015 – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announces its meetings with the investors and shareholders during the second semester 2015.

September 16, 2015	11:30am: - Analyst and Investor Meeting 5:30pm: Audio/web conference
September 22, 2015	InvestorDagen Radisson Blu Scandinavia Hotel – Copenhagen, Denmark
October 7 & 8, 2015	European Large & Midcap Event Palais Brongiart, Paris
November 5, 2015	Société Générale CIB Healthcare & Biotechnology Conference Pavillon Ledoyen, Paris
November 20 & 21, 2015	Salon Actionaria Palais des Congrès, Paris
November 24, 2015	Natixis Small & Mid Caps Conference Pavillon Gabriel, Paris

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to "make the difference". The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.

Key orphan oncology products at the advanced development stage are:

Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad® ): Phase II in severe oral mucositis: Positive final results Beleodaq® (belinostat): registered in the US in 2 nd line treatment of peripheral T-cell lymphoma For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website (http://www.amf-france.org) or on the company's website (www.onxeo.com).